All In Biotech

Drug Trial Radar · NCT06393738

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

A Phase 1 First in Human Study of ARV-393 in Adult Participants With Advanced Non-Hodgkin's Lymphoma

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

329

Planned (sponsor's estimate)

Start

Sep 5, 2024

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Arvinas Inc.Industry
Sponsor type
Industry
First posted
May 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.

Conditions

  • Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
  • Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

Interventions

  • ARV-393Drug

    Oral daily dose of ARV-393 at a specified dose level

  • GlofitamabDrug

    Glofitamab infusion per labelled prescribing information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities During First 28 DaysTime frame: 28 days from first study dosing
  2. Percentage of Participants With Adverse Events Characterized by Severity, Seriousness, and Relationship to Study Drug as a Measure of Safety and TolerabilityTime frame: Parts A and B: From the study baseline to 30 days after last dose of ARV-393; Parts C and D: From the study baseline to 40 days after last dose of ARV-393
  3. Number of Participants With Abnormal Vital Signs, Abnormal ECG Readings (QT Interval) and Abnormal Laboratory ParametersTime frame: Parts A and B: From the study baseline to 30 days after last dose of ARV-393; Parts C and D: From the study baseline to 40 days after last dose of ARV-393
  4. Percentage of Participants With Grade 3 or Grade 4 Clinical Lab Abnormalities Using the Common Terminology Criteria for Adverse Events (CTCAE) With Scale From Grade 1 Grade 5. Higher Score Means Worse OutcomeTime frame: Parts A and B: From the study baseline to 30 days after last dose of ARV-393; Parts C and D: From the study baseline to 40 days after last dose of ARV-393

Locations

21 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    New Haven, Connecticut · Recruiting

  • Clinical Trial Site

    Miami, Florida · Recruiting

  • Clinical Trial Site

    Detroit, Michigan · Recruiting

  • Clinical Trial Site

    New Brunswick, New Jersey · Recruiting

  • Clinical Trial Site

    New York, New York · Recruiting

  • Clinical Trial Site

    New York, New York · Recruiting

  • Clinical Trial Site

    Cleveland, Ohio · Recruiting

  • Clinical Trial Site

    Nashville, Tennessee · Withdrawn

  • Clinical Trial Site

    Houston, Texas · Recruiting

  • Clinical Trial Site

    Charlottesville, Virginia · Recruiting

  • Clinical Trial SIte

    East Melbourne, Victoria, Australia · Recruiting

  • Clinical Trial SIte

    Calgary, Alberta, Canada · Recruiting

  • Clinical Trial Site

    Toronto, Ontario, Canada · Recruiting

  • Clinical Trial Site

    Montreal, Quebec, Canada · Recruiting

  • Clinical Trial Site

    Copenhagen, Denmark · Recruiting

  • Clinical Trial Site

    Odense C, Denmark · Recruiting

  • Clinical Trial Site

    Barcelona, Spain · Recruiting

  • Clinical Trial Site

    Madrid, Spain · Recruiting

  • Clinical Trial Site

    Salamanca, Spain · Recruiting

  • Clinical Trial Site

    El Palmar, Murcia, Spain · Recruiting

  • Clinical Trial Site

    Pamplona, Navarre, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.